Wang Qian, Long Yu, Hang Ai, Zan Gui-Ying, Shu Xiao-Hong, Wang Yu-Jun, Liu Jing-Gen
College of Pharmacy, Dalian Medical University, Dalian, 116044, China.
Pharmacology and Toxicology Department, Shanghai Institute for Food and Drug Control, Shanghai, 201203, China.
Psychopharmacology (Berl). 2016 Jun;233(12):2411-8. doi: 10.1007/s00213-016-4292-z. Epub 2016 Apr 26.
Opioid receptors are implicated in the regulation of motivation and emotion. However, animal studies show that activation of κ opioid receptor produces contrasting mood-altering effects in models of anxiety-like and depressive-like behaviors, and consequently, the role of κ receptor in mood control remains unsettled. The effect of κ/μ opioid combination in emotion regulation was unexplored.
The aim of the study was to investigate the effects of (-)-3-N-ethylaminothiazolo [5,4-b]-N-cyclopropylmethylmorphinan hydrochloride (ATPM-ET), a novel κ agonist and μ partial agonist, in regulating emotional responses.
The emotional responses of ATPM-ET were detected in the elevated plus maze (EPM), open field test (OFT), forced swim test (FST), and tail suspension test (TST). Selective κ antagonist nor-binaltorphimine (nor-BNI) and μ antagonist β-funaltrexamine (β-FNA) were applied to determine the type of receptor involved. The conditioned place aversion model was used to evaluate the effects on aversive emotion.
In the EPM and OFT, ATPM-ET (1 and 2 mg/kg, s.c.) significantly increased the time spent in the open arm and in the central area, respectively. In the FST and TST, ATPM-ET (0.5 and 1 mg/kg, s.c.) significantly reduced the duration of immobility. These effects were prevented by nor-BNI (10 mg/kg, i.p., -24 h), but not by β-FNA (10 and20 mg/kg, i.p., -24 h) pretreatment. At the dose of 2 mg/kg, ATPM-ET did not induce conditioned place aversion.
ATPM-ET, at doses from 0.5 to 2 mg/kg, produced anxiolytic- and antidepressant-like effects without inducing aversive emotion. These effects were more closely mediated by activation of κ receptor than μ receptor.
阿片受体参与动机和情绪的调节。然而,动物研究表明,κ阿片受体的激活在焦虑样和抑郁样行为模型中产生相反的情绪改变效应,因此,κ受体在情绪控制中的作用仍未确定。κ/μ阿片类药物联合在情绪调节中的作用尚未得到探索。
本研究旨在探讨新型κ激动剂和μ部分激动剂盐酸(-)-3-N-乙基氨基噻唑并[5,4-b]-N-环丙基甲基吗啡喃(ATPM-ET)在调节情绪反应中的作用。
在高架十字迷宫(EPM)、旷场试验(OFT)、强迫游泳试验(FST)和悬尾试验(TST)中检测ATPM-ET的情绪反应。应用选择性κ拮抗剂 nor-纳洛酮啡(nor-BNI)和μ拮抗剂β-氟纳曲胺(β-FNA)来确定所涉及的受体类型。采用条件性位置厌恶模型评估对厌恶情绪的影响。
在EPM和OFT中,ATPM-ET(1和2mg/kg,皮下注射)分别显著增加了在开放臂和中央区域的停留时间。在FST和TST中,ATPM-ET(0.5和1mg/kg,皮下注射)显著缩短了不动时间。这些效应被nor-BNI(10mg/kg,腹腔注射,-24小时)预处理所阻断,但未被β-FNA(10和20mg/kg,腹腔注射,-24小时)预处理所阻断。在2mg/kg剂量下,ATPM-ET未诱导条件性位置厌恶。
ATPM-ET在0.5至2mg/kg剂量下产生抗焦虑和抗抑郁样效应,且不诱导厌恶情绪。这些效应更多地是由κ受体而非μ受体的激活介导的。